Diaryl Ether Pyrrolo Benzodiazepine Hybrids for DNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pyrrolo[2,1-c][1,4]benzodiazepine antitumor antibiotics face limitations such as poor water solubility, cardio toxicity, and development of drug resistance, hindering their clinical efficacy.
Innovation Solution
Development of diaryl ether linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids with varying alkyl chain lengths, which are synthesized through specific chemical reactions to enhance DNA binding activity and anticancer properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pyrrolo[2,1-c][1,4]benzodiazepine antitumor antibiotics are used, then DNA binding activity is achieved, but water solubility is poor
Solution Approach 1:
The molecule is divided into two functional segments: a PBD unit for DNA binding and a phenoxyl alkyl ether unit for solubility enhancement. This segmentation allows each part to fulfill its specific function independently, resolving the contradiction between DNA binding activity and water solubility.
Solution Approach 2:
The patent creates a hybrid compound combining PBD (pyrrolo[2,1-c][1,4]benzodiazepine) and phenoxyl alkyl ether moieties. This composite structure integrates the DNA-binding capability of PBD with the solubility-enhancing properties of phenoxyl alkyl ether, simultaneously achieving both desired properties.
2Reliability
If pyrrolo[2,1-c][1,4]benzodiazepine antitumor antibiotics are used, then DNA binding activity is achieved, but cardio toxicity occurs
Solution Approach 1:
By separating the DNA-binding function (PBD unit) from the solubility function (phenoxyl alkyl ether unit), the patent reduces the dosage required for effective DNA binding, thereby minimizing cardio toxicity associated with higher doses of conventional PBD antibiotics.
Solution Approach 2:
The patent modifies the chemical structure by introducing phenoxyl alkyl ether groups, which change the physical and chemical parameters of the molecule. This structural modification enhances solubility and reduces toxicity while maintaining DNA binding activity.
3Reliability
If pyrrolo[2,1-c][1,4]benzodiazepine antitumor antibiotics are used, then DNA binding activity is achieved, but drug resistance develops
Solution Approach 1:
The hybrid structure combining PBD and phenoxyl alkyl ether creates a novel compound with improved pharmacological properties. The phenoxyl alkyl ether component enhances cellular uptake and stability, reducing the development of drug resistance while maintaining effective DNA binding.
Solution Approach 2:
Structural modification through the addition of phenoxyl alkyl ether groups changes the molecular parameters, including solubility, stability, and cellular permeability. These parameter changes improve the drug's effectiveness and reduce resistance development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The diaryl ether linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids demonstrate improved DNA binding affinity and potent anticancer activity across various human cancer cell lines, with specific compounds showing effective concentration ranges for GI50 values.
Implementation Method 1
These antibiotics react covalently with DNA to form an N2-guanine adduct that lies within the minor groove of duplex DNA via an acid-labile aminal bond to the electrophilic imine at the N10-C11 position
Data Source
AI summary
The present invention provides a compound of general formula A, useful as potential anticancer agents against eleven human cancer cell lines. The present invention further provides a process for the preparation of diaryl ether linked pyrrolo[2,1-c][1,4]benzodi azepine conjugates attached through different alkane spacers of general formula A.